Menu

1 / 35

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing - Zai Lab (NAS

Top Stories Feed·Vandana Singh·3 days ago
#dswfmaaK
#benzinga#half#atopic#dermatitis#stock
Reading 0:00
15s threshold

November 13, 2026 1:02 PM 2 min read

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing

by Vandana Singh Benzinga Staff Writer

Follow

ZLABZai Lab Ltd

$24.21-7.01%

Stock Score Locked: Want to See it?

Benzinga Edge Rankings give you vital metrics on any stock – anytime.

Reveal Full Score Edge Rankings

Momentum85.05

GrowthN/A

QualityN/A

ValueN/A

Price Trend

ShortMediumLongOverview Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis.

Strong Biomarker Inhibition And Extended Half-Life

Data from 48 healthy volunteers showed that ZL-1503 rapidly and sustainably blocked the IL-13 pathway.

A single dose of 200 mg or higher inhibited phosphorylated STAT6, a key atopic dermatitis signaling biomarker, by at least 90% through Week 12.

The treatment also lowered circulating type 2…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.